Ryan Baldridge

Ryan Baldridge
Associate Professor of Biological Chemistry
Medical School
[email protected]
Available to mentor
Ryan Baldridge
Ryan Baldridge
Associate Professor
  • About
  • Links
  • Qualifications
  • Research Overview
  • Recent Publications
  • Manage Your Profile

  • About

    I grew up in Northern Kentucky and attended Northern Kentucky University as an undergraduate student. During this time, I worked at the Wood Hudson Cancer Research Laboratory with Dr. Bonnie Richmond and later in the lab of Dr. Patrick Schultheis at Northern Kentucky University. I graduated with two BS degrees in 2007 (in Biological Sciences and Chemistry). My PhD training was with Todd Graham at Vanderbilt University where I worked on mechanics of phospholipid "flippases", graduating in 2013. I completed my postdoctoral training with Tom Rapoport at Harvard Medical School in 2017, working on mechanics of the the endoplasmic reticulum associated degradation system (ERAD). I started my lab at the University of Michigan Medical School in September 2017.

    Links

    • Baldridge Lab

    Qualifications

    • Damon Runyon Cancer Research Foundation Fellow
      Harvard Medical School, Cell Biology, United States
      2013 - 2017
      Postdoctoral Fellowship
    • PhD, Biological Sciences
      Vanderbilt University, Nashville, TN, United States
      2007 - 2013
    • BS, Biological Sciences
      Northern Kentucky University, Highland Heights, KY, United States
      2003 - 2007
    • BS, Chemistry
      Northern Kentucky University, Highland Heights, KY, United States
      2003 - 2007

    Research Overview

    We are interested in the basic mechanisms of protein quality control systems at cellular membranes. We study how these systems select their substrates, and aim to identify the cellular pathways regulated by them. These processes are important in pathologies related to cell stress, protein misfolding, and protein misregulation. Human illnesses linked to these problems include Parkinson’s disease, Alzheimer’s disease, and various cancers. Our longer-term goals are to understand how changing conditions in cells target substrate proteins to these integral-membrane quality control systems and exploit these systems to enable targeted protein degradation from cellular organelles.

    Recent Publications

    See All Publications
    • Journal Article
      Competition between Der1 and ERAD-M substrates controls Hrd1 complex function
      Russ JE, Peterson BG, Taylor S, Baldridge RD. Proceedings of the National Academy of Sciences of the United States of America, 2025 Dec 29; 122 (49): e2513595122 - e2513595122. DOI:10.1073/pnas.2513595122
    • Journal Article
      Ubiquitin chain variability directs substrates of the Tul1 ubiquitin ligase complex to different degradation pathways
      Dennison DD, Baldridge RD. Journal of Cell Biology, 2025 Sep 1; 224 (9): DOI:10.1083/jcb.202312133
      PMID: 40694054
    • Journal Article
      Direct observation of autoubiquitination for an integral membrane ubiquitin ligase in ERAD.
      Moochickal Assainar B, Ragunathan K, Baldridge RD. Nat Commun, 2024 Sep 12; 15 (1): 1340 - 1340. DOI:10.1038/s41467-024-45541-3
    • Journal Article
      Deep mutational scanning highlights a role for cytosolic regions in Hrd1 function.
      Peterson BG, Hwang J, Russ JE, Schroeder JW, Freddolino PL, Baldridge RD. Cell Rep, 2024 Sep 12; 42 (11): 113451 - 113451. DOI:10.1016/j.celrep.2023.113451
    • Journal Article
      The ERAD system is restricted by elevated ceramides.
      Hwang J, Peterson BG, Knupp J, Baldridge RD. Sci Adv, 2024 Sep 12; 9 (2): eadd8579 - eadd8579. DOI:10.1126/sciadv.add8579
    • Journal Article
      Cycles of autoubiquitination and deubiquitination regulate the ERAD ubiquitin ligase Hrd1.
      Peterson BG, Glaser ML, Rapoport TA, Baldridge RD. eLife, 2024 Sep 12; 8: e50903 - e50903. DOI:10.7554/eLife.50903
    • Journal Article
      Autoubiquitination of the Hrd1 Ligase Triggers Protein Retrotranslocation in ERAD.
      Baldridge RD, Rapoport TA. Cell, 2024 Sep 12; 166 (2): 394 - 407. DOI:10.1016/j.cell.2016.05.048
    • Journal Article
      Type IV P-type ATPases distinguish mono- versus diacyl phosphatidylserine using a cytofacial exit gate in the membrane domain.
      Baldridge RD, Xu P, Graham TR. J Biol Chem, 2024 Sep 12; 288 (27): 19516 - 19527. DOI:10.1074/jbc.M113.476911

    Featured News & Stories

    headshot of Jeffrey Knupp
    Department News

    Jeffrey Knupp, PhD, receives a postdoctoral fellowship from the Michigan Pioneer Fellows Program

    U-M Biological Chemistry research fellow Jeffrey Knupp of the Baldridge lab receives a postdoctoral fellowship.
    headshot of Basila Moochickal Assainar
    Department News

    Congratulations to Basila Moochickal Assainar, PhD

    Biological Chemistry PhD student Basila Moochickal Assainar of the Baldridge and Ragunathan labs defends her doctoral dissertation.
    Headshots of five Biological Chemistry faculty promoted in 2025
    Department News

    Five Biological Chemistry faculty members receive promotions in 2025

    Biological Chemistry faculty members Ryan Baldridge, PhD, Kevin Bohannon, PhD, Lydia Freddolino, PhD, Tobias Giessen, PhD, and Jeremy Schroeder, PhD, have been promoted.
    photos of award winners and a trophy
    Department News

    Ryan Baldridge and Andrew Shurer receive Endowment for Basic Science Awards

    Assistant Professor Ryan Baldridge and Research Lab Specialist Andrew Shurer are the 2024 recipients of Endowment for Basic Science (EBS) Awards for the Department of Biological Chemistry at U-M Medical School.
    Schematic of Hrd1 proteoliposome immobilization
    Department News

    PhD student Basila Moochickal Assainar publishes a research article in Nature Communications

    PhD student Basila Moochickal Assainar is the first author of a research article in Nature Communications.
    Department News

    Ryan Baldridge and Billy Tsai received a W.M. Keck Foundation Award

    The W.M. Keck Foundation has awarded $1.3M to Assistant Professor Ryan Baldridge, Biological Chemistry, and Corydon Ford Collegiate Professor Billy Tsai, CDB, to develop a next-generation protein degradation technology to revolutionize antiviral treatments for endoplasmic reticulum (ER) dysfunction.